What Iterion Therapeutics does

Iterion Therapeutics is a clinical-stage biopharmaceutical company headquartered in Houston, Texas, developing small-molecule therapeutics for cancers driven by dysregulated Wnt/beta-catenin signaling. The company's lead and sole clinical asset, tegavivint (formerly BC2059), is a first-in-class small-molecule inhibitor of TBL1 (Transducin beta-like protein 1) that disrupts the TBL1-beta-catenin transcriptional complex and selectively degrades nuclear beta-catenin, a mechanism intended to address a previously 'undruggable' node in the Wnt pathway without the toxicities of upstream inhibitors. Iterion also has early R&D into second-generation TBL1 inhibitors, suggesting a platform ambition beyond the lead asset.

The company's primary clinical focus is advanced hepatocellular carcinoma (HCC), where approximately 40% of patients harbor Wnt/beta-catenin mutations and no targeted therapies exist. Phase 1/2 data presented at ASCO 2026 showed a 22% overall response rate, 89% disease control rate, and 8-month median progression-free survival in second- and third-line WPAM+ patients, with a favorable safety profile. Beyond HCC, Iterion is expanding tegavivint into metastatic colorectal cancer (Phase 1/2 trial initiated March 2026 in Houston), relapsed/refractory pediatric osteosarcoma (trial initiated February 2026 at Emory/Aflac Cancer Center with FDA Orphan Drug and Pediatric Rare Disease Designations), and earlier-stage signals in desmoid tumors, large B-cell lymphomas, AML, and NSCLC via investigator-sponsored collaborations with Ohio State, the Children's Oncology Group, and Cancer Research UK.

Iterion is a privately held, pre-revenue company that funds development through a mix of non-dilutive grants and equity. Major capital includes $26 million in CPRIT Product Development Awards and a $17 million financing round led by Lumira Ventures with Sante Ventures and Viva BioInnovator participation; the board also includes representatives from OrbiMed and Lumira. The company employs 11–50 people and is led by CEO Rahul Aras (PhD), CMO Ovid Trifan (MD, PhD), CSO Steve Horrigan (PhD), and COO Jean Chang, with founder Sunil Sharma. The go-to-market upon potential FDA approval is expected to rely on enterprise field sales to oncologists and hospital systems, with the addressable market spanning more than 500,000 Wnt-driven cancers annually across multiple indications.

Name

Iterion Therapeutics

Legal name

Iterion Therapeutics

Website

https://iteriontherapeutics.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing tegavivint, a first-in-class TBL1 inhibitor targeting Wnt/beta-catenin-driven cancers. Its lead indication is advanced hepatocellular carcinoma, with expansion trials underway in colorectal cancer and pediatric osteosarcoma.

Ownership category

akta.pro rank

Product category

Targeted Oncology Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

akta.pro secondary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Cancer therapeutics
• Wnt pathway inhibitors
• Clinical-stage biopharmaceutical
• Targeted oncology drugs
• Small molecule therapeutics

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Drug Sales: Pre-revenue clinical-stage biopharmaceutical company. Upon successful clinical development and FDA approval, Iterion intends to commercialize tegavivint for Wnt-driven cancers including hepatocellular carcinoma, colorectal cancer, and osteosarcoma.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing tegavivint, a first-in-class small-molecule TBL1 inhibitor that selectively degrades nuclear beta-catenin to shut down oncogenic Wnt/β-catenin signaling. The lead product is being advanced in clinical trials across multiple Wnt-driven cancer indications including advanced hepatocellular carcinoma, metastatic colorectal cancer, and pediatric osteosarcoma.

Product overview

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing a single lead product, tegavivint, as a first-in-class small molecule inhibitor targeting the Wnt/β-catenin pathway. Tegavivint is being advanced across multiple cancer indications including advanced hepatocellular carcinoma (HCC), metastatic colorectal cancer, osteosarcoma, desmoid tumors, large B-cell lymphomas, acute myeloid leukemia, and non-small cell lung cancer. The company's differentiated approach targets TBL1 to promote nuclear β-catenin degradation, positioning tegavivint as the most advanced Wnt/β-catenin inhibitor in clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

• Tegavivint Tegavivint is a first-in-class small-molecule TBL1 inhibitor that selectively degrades nuclear beta-catenin to shut down oncogenic Wnt/β-catenin signaling. It is the most advanced Wnt/β-catenin inhibitor in clinical development, with applicability across more than 500,000 cancers annually, and is being evaluated in advanced hepatocellular carcinoma (primary focus), metastatic colorectal cancer, and pediatric osteosarcoma.

Quantifiable outcome

• 22% overall response rate in Phase 1/2 trial for advanced HCC
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Emory University / Aflac Cancer and Blood Disorders Center of Children's Healthcare of AtlantacoreImplementation/ SI/ Consulting Partner · 10 February 2026Emory University-sponsored clinical trial evaluating tegavivint in combination with gemcitabine for patients with relapsed or refractory osteosarcoma. The trial is conducted at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta.
• Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research InstituteminorImplementation/ SI/ Consulting PartnerCollaboration with Ohio State University Comprehensive Cancer Center for Phase 1 clinical trial of tegavivint in patients with c-Myc-overexpressing relapsed or refractory large B-cell lymphomas.
• Children's Oncology Group Pediatric Early Phase Clinical Trials NetworkcoreImplementation/ SI/ Consulting PartnerNCI-supported clinical trials group sponsoring the first clinical study for tegavivint in the pediatric population, representing an investigator-sponsored Phase 1/2 clinical trial in pediatric cancers.
• Cancer Research UK (CRUK)minorStrategic or Co-development PartnerCollaboration with Cancer Research UK on preclinical study of tegavivint in beta-catenin mutant hepatocellular carcinoma, with results presented at the 34th EORTC-NCI-AACR Symposium.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Erasca: Clinical-stage precision oncology company targeting the RAS/MAPK pathway. Comparable as a similarly-sized clinical-stage biotech with a single mechanistic focus and multi-indication development strategy, though in a different signaling pathway.
• Theseus Pharmaceuticals: Clinical-stage targeted oncology company developing kinase inhibitors across multiple indications. Comparable as a venture-backed clinical-stage oncology company with pipeline breadth across tumor types.
• Revolution Medicines: Clinical-stage precision oncology company developing targeted therapies for RAS-driven cancers. Comparable as a clinical-stage biotech with a first-in-class mechanism targeting a historically difficult oncology pathway.
• Foghorn Therapeutics: Clinical-stage oncology biotech developing chromatin-based therapeutics. Comparable as a clinical-stage company targeting transcriptional regulation machinery in cancer with a first-in-class mechanism.
• Black Diamond Therapeutics: Clinical-stage precision oncology company developing allosteric mutation-targeted therapies. Comparable as a venture-backed clinical-stage biotech with a mechanism-focused discovery approach.
• Nuvalent: Clinical-stage precision oncology company developing targeted kinase inhibitors. Comparable as a clinical-stage biotech focused on a single mechanism deployed across multiple oncology indications.
• Day One Biopharmaceuticals: Clinical-stage pediatric and adult oncology company with FDA breakthrough and orphan designations. Comparable as a clinical-stage oncology company pursuing pediatric rare cancer indications with regulatory designations.
• Cogent Biosciences: Clinical-stage targeted oncology company developing kinase inhibitors. Comparable as a venture-backed clinical-stage precision oncology biotech with multi-indication development strategy.

Emerging players

• Surrozen: Clinical-stage biotech developing Wnt pathway-targeting therapeutics for regenerative medicine and ophthalmology. Comparable through direct targeting of the same Wnt signaling pathway, though in different therapeutic areas.

Broad incumbents

• Genentech (Roche): Large oncology incumbent developing multiple targeted therapies including HCC therapies (atezolizumab+bevacizumab standard of care). Comparable as the dominant incumbent in the HCC and broader oncology landscape Iterion operates in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iterion Therapeutics